CareDx Extends Artificial Intelligence Leadership to Heart Transplantation

New Addition to CareDx HeartCare Multimodality Portfolio Can Enable More Precise, Personalized Patient Care

SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that through its ongoing partnership with OrganX, a non-profit health organization focused on cutting-edge digital health solutions, it plans to expand its HeartCare multimodality portfolio with a new artificial intelligence (AI) prognostic for cardiac allograft vasculopathy (CAV).
Read the complete press release on CareDx.com.